Shares of Sanofi SA (SNYNF,SNY) were losing around 2 percent in the morning trading in Paris after the French drug giant reported Thursday a decline in third quarter profit, while net sales were slightly higher amid negative currency …
Today, we’ll talk about the prescription numbers, what we’re seeing from the …
Sanofi Launches "Action 2017", a Worldwide Employee Stock Purchase Plan Paris, France - June 15, 2017 - Sanofi (http://en.sanofi.com/index.aspx) announced today the launch of "Action 2017", a worldwide stock purchase plan …
At this point, bad news is coming in consistently to the point that any significant piece of good news could catapult the stock higher, making Sanofi an interesting choice for dip-buyers. The latest setback the company has had stems from …
At the heart of the standoff over Sanofi's (SNY) $20 billion takeover of Genzyme was the value of a multiple sclerosis drug. Genzyme argued that the drug Lemtrada's market potential was not being recognized in Sanofi's offering price. After …
After declining in 2016, share price of French pharma giant Sanofi SNY has picked up in 2017. This Zacks Rank #2 (Buy) stock has risen 21.1% this year so far, outperforming the return of the Zacks classified Large-Cap Pharma industry of …
PARIS, FRANCE - November 30, 2017 - Elias Zerhouni, M.D., President of Sanofi R & D was awarded 'Executive of the …
MENAFN1mon
The analyst in Paris also doubted the news would be reflected in Sanofi's stock price. The stock has risen 18.5 percent since the beginning of the year. Sanofi closed today at 372.1 francs, down 3.3 francs, or 0.9 percent.
If you want a Stock Review on PFE, SNY, HRTX, or AERI then come over to http://dailystocktracker.com/register/ and …